DATE: September 23, 2016 TIME: 9:00 AM PST, 12:00 PM ET
As genetic testing becomes more pervasive, many clinical and pathology laboratories see next generation sequencing (NGS) as an attractive evolution of their lab’s testing capabilities. There is already precedent for reimbursement by private and public insurers for genetic testing, particularly NGS genetic testing. However the decision to choose a genetic test that has a large market potential, is reimbursable (or willingly paid for out-of-pocket), and is easy to implement is daunting. One such test that meets all three business needs is the non-invasive prenatal test (NIPT). NIPT is applicable to a very large market (ca. 136.8M births per year globally). It is reimbursed by more private or government insurance and is readily paid for by consumers directly. The test is now easily implemented in most laboratories through Natera’s technology licensing program. Natera has invested 10s of millions of dollars in research and development and makes these technologies available to licensees under its technology licensing program. By licensing from Natera, laboratories can access some of the same technologies employed for Natera’s Panorama NIPT. This includes key Natera reagents, bioinformatics algorithms, and scientific resources used to develop a powerful NIPT offering. This webinar will introduce Natera’s technology licensing program and explain the process in which prospective licensee labs may license key Natera technology to perform NIPT in their own labs thereby offering a market leading NIPT in their own market.
*Only available in certain geographies. Talk with your local representative for availability in your country*